We investigated a family with a brachydactyly type A2 and identified a heterozygous arginine to glutamine (R380Q) substitution in the Growth/Differentiation Factor 5 (GDF5) in all affected individuals. The observed mutation is located at the processing site of the protein, at which the GDF5 precursor is thought to be cleaved releasing the mature molecule from the prodomain. In order to test the effect of the mutation, we generated the GDF5-R380Q mutant and a cleavage-resistant proGDF5 mutant (R380A/R381A) in vitro. Both mutants were secreted from chicken micromass cultures, but showed diminished biological activity.
Introduction
Transforming growth factor β (TGFβ) superfamily proteins such as bone morphogenetic proteins (BMPs) promote cellular proliferation, differentiation and regeneration.
Growth/differentiation factor 5 (GDF5, also known as CDMP1 or BMP14) is a protein belonging to the GDF-subgroup of BMPs with a characteristic developmental expression pattern in precartilage condensations and in the developing cartilaginous joints (1) . The main effects of GDF5 appear to be the induction of cartilage and the patterning of joints, as shown by various in vitro and in vivo experiments (2) (3) (4) . The ability of GDF5 to induce cartilage and bone has made GDF5 an attractive factor for medical applications such as spine fusions (3) and disc regeneration (5, 6) . Furthermore, it has been shown that GDF5 has trophic and protective effects on dopaminergic neurons in vitro (7) and in vivo (8) . Like other members of the TGFβ protein family, GDF5 is initially synthesized as a large precursor protein (proGDF5) consisting of 501 amino acids including an N-terminal signal peptide of 27 amino acids length (9) . Based on data obtained with other BMPs, proGDF5 is thought to undergo proteolytic cleavage at a cluster of basic residues (RX(K/R)R) at position 381 (10) (11) (12) ) (13) . The mature GDF5 protein consists of 120 amino acids which form homo-or possibly also heterodimers with other BMPs that are linked via a disulfide-bridge.
For BMP4 it was shown that endoproteolytic cleavage of the precursor primarily takes place at the multibasic motif RSKR by specific members of the subtilisin-like proprotein convertase (SPC) family of endoproteases. In mammals seven members of this family have been characterised that show distinct substrate specificity and expression patterns (14) . The at Pennsylvania State University on http://hmg.oxfordjournals.org/ Downloaded from prototype of the SPC family, furin (also known as SPC1) as well as PACE4 (also known as SPC4) and PC6 (also known as SPC6) do also recognise the consensus sequence RXR/KR but can additionally cleave after the minimal sequence RXXR. This principle applies also for GDF5 and sequence homologies with the BMPs and the presence of a SPC recognition site suggests a similar mechanism (15) . The presence of at least some of these SPCs in the extracellular space, like SPC4 and SPC6, also suggests that the activity of secreted proBMP as well as proGdf5 might be regulated in situ via proteolytic cleavage (16) .
Other mechanisms that regulate BMP activity in the extracellular space include binding to antagonistic proteins such as Noggin (NOG) and Chordin that block activation of cell surface receptors. Proteases such as Tolloid can cleave Chordin to liberate BMP4 (17) . Furthermore, several BMPs were shown to bind to surface heparin sulfate proteoglycans, a mechanism that can promote or restrict activity (18) . Upon binding of BMPs/GDFs to their cognate BMPreceptors SMADs (SMAD1, 5, 8) are activated and translocated into the nucleus where they bind to specific sequences of the DNA to activate target genes. BMP signalling is negatively regulated by inhibitory SMADs (SMAD6,7) which block transmission of signals from the membrane to the nucleus (19) .
The importance of GDF5 is underlined by a number of clinical syndromes associated with mutations in GDF5 or its receptor BMP receptor 1B (BMPR1B) (20, 21) . Heterozygous loss of function mutations in GDF5 cause brachydactyly type C (BDC), a condition characterised by a specific pattern of shortened digits and supernumerary ossifications of phalanges.
Homozygous loss-of-function mutations in GDF5 result in the acromesomelic chondrodysplasias of the Grebe, Hunter-Thompson, or DuPan type. A specific point mutation in GDF5 (L441P) was shown to interfere with receptor binding and consequently has reduced biological activity. This is associated with brachydactyly type A2 (BDA2) (22) , a condition that can also be caused by dominant negative mutations in the gene encoding for BMPR1B (23, 24) . In contrast, activating mutations in GDF5 (R438L) result in symphalangism (fusion of finger joints) which can also be caused by mutations in the BMP-inhibitor NOG (22, 25) .
In the family described here, a genetic analysis revealed a mutation in GDF5 at position 380 (R380Q), located at the GDF5 processing site. To test the hypothesis that the skeletal defect is due to abnormal cleavage at the proGDF5 precursor maturation site we generated GDF5 mutants and tested them in vitro. To further investigate the processing requirements for proGDF5, we produced recombinant proGDF5 in E. coli. We found that unprocessed (rh) proGDF5 is virtually biologically inactive, and, in contrast to mature GDF5, soluble at neutral pH. (rh) ProGDF5 can be proteolytically cleaved by intracellular as well as extracellular proteases thus generating biological active mature GDF5. Our results indicate that full length (rh) proGDF5, like mature rhGDF5, has the potential to be used as a drug in regenerative medicine.
Results
Brachydactyly caused by a mutation in the SPC cleavage site of GDF5
We identified a family with a brachydactyly phenotype that showed a dominant pattern of inheritance (Fig. S1 ). Hands and feet were clinically examined in 28 family members of whom 14 were affected. Radiographs were available from 5 affected individuals and metacarpophalangeal profiling (Fig. 1 ) was performed as described previously (26) . In four of five radiographically evaluated cases the 2 nd mesophalanx was shortened by more than 2 SD (Fig. 1) . The metacarpophalangeal profile (MCPP) demonstrated that the second mesophalanx was constantly (five out of five subjects) shorter than mesophalanges 3, 4, and 5 which is in accordance with a diagnosis of BDA2. Other occasional findings were a relatively short first metacarpal (V:2) or first proximal phalanx (V:9). The characteristic MCPP was also evident indicating overlap with BDA1 and BDC (Fig. 1) . One affected family member in addition had a congenital heart defect (type unknown) which is regarded as unrelated to the identified mutation.
BDA2 is known to be associated with mutations in BMPR1B. However, no mutations in BMPR1B were identified. As GDF5 mutations are known to cause both BDA2 and BDC, we subsequently focused on this gene. Mutation analysis of GDF5 revealed a missense mutation in all affected at position c.1139 from G to A resulting in an exchange of arginine for glutamine at position 380 (R380Q).
Investigation of GDF5 R380Q in micromass culture
In contrast to other TGFβ family protein members, GDF5 has two superimposed SPC processing sites, consisting of two RXXR motifs (RRKRR, Fig. 2 ). The R380Q mutation is located at the P2 position of the SPC processing site of GDF5 disrupting one of the two general motifs (Fig. 2) . To investigate the functional consequences of the R380Q mutation, we performed site directed mutagenesis of cloned full length human GDF5 cDNA in order to produce a) the R380Q mutation and b) to inactivate the SPC processing site completely by converting the two arginines at positions 380 and 381 to alanines (R380A/R381A). The mutagenised cDNA clones were verified by sequencing and cloned into the replication competent avian sarcoma (RCAS) retroviral vector system. RCAS retrovirus is avian specific and allows the infection of chick cells to almost 100% (22) . We used this system to overexpress wt and mutant GDF5 in mesenchymal stem cells prepared from chick limb buds. (Fig. 3 A,B) .
To investigate the consequences of both mutations on prodomain cleavage we performed
Western blots against GDF5 in the supernatant and cell lysates of micromass cells infected with RCAS expressing wt or mutant GDF5. Using the monoclonal antibody aMP5 against rhGDF5, we detected both proGDF5 and mature rhGDF5 (Fig. 3C ). Under non-reducing conditions proGDF5 migrates at about 100 kDa and mature rhGDF5 at 25 kDa. In addition intermediate cleavage products were visible at 50-80 kDa. We observed strong staining for full length GDF5 in the cellular supernatant indicating that GDF5 is efficiently secreted in this experimental setting. In addition to the full length band we observed a smaller band corresponding to processed mature GDF5. The latter band was absent in the R380Q and R380A/R381A mutants indicating that both mutations interfere with GDF5 processing.
Moreover, these results suggest that disrupting the P2 position appears sufficient to inhibit the processing significantly and this effect is not compensated for by an intact P1 position.
Expression and purification of (rh) proGDF5
In order to investigate the properties and function of proGDF5 in more detail we produced recombinant (rh) proGDF5 protein. (Fig. 4A ). To initiate protein expression, the N-terminus of proGDF5 was modified by introducing a sequence tag.
The purification process comprises a direct refolding step. Thus, after inclusion body preparation the proteins can be used directly in the refolding without prior column purification. The direct refolding process for (rh) proGDF5 was optimised to generate correctly refolded dimeric protein with efficiency greater than 80% (Fig. 4B ). The refolding process was almost completed after 2 days of incubation. Non-refolded protein and remaining E. coli host proteins were removed using a combination of size exclusion and reversed phase chromatography (RP HPLC). After successful refolding, correctly refolded protein migrates under non-reducing conditions at around 100 kDa. The resulting purity of proGDF5 was greater than 90 %, as determined by SDS-PAGE followed by Coomassie staining (Fig. 4C ).
Solubility testing of (rh) proGDF5
Mature rhGDF5 has an isoelectric point of 7.6 and is therefore nearly insoluble under physiological conditions (27) . To assess whether (rh) proGDF5 shows an improved solubility in aqueous solutions at neutral pH, (rh) proGDF5 was dissolved in buffers ranging from pH 2.0 to 12.0. (rh) proGDF5, unlike its mature counterpart, is soluble at physiological pH in buffers such as PBS (Fig. 5 ). Solubility of (rh) proGDF5 was best at pH 2; proGDF5 was nearly insoluble at its predicted isoelectric point at pH 10.
Proteolytic cleavage of (rh) proGDF5
Members of the TGFβ protein family are initially synthesised as large precursor proteins which undergo proteolytic cleavage to release the active part of the protein. In analogy to proBMP4 and proBMP2 (10) (11) (12) 28) , it is thought that proGDF5 is processed in a similar way to mature GDF5. We investigated proteases of different classes which might be involved in protein maturation. (rh) proGDF5 was digested with furin, MMP3 and trypsin separated under non-reducing conditions on a 10% PAGE and detected via Western blotting.
The subtilisin like protein convertase furin acts intracellularly in the trans golgi network, but furin can also be posttranslationally modified to produce a smaller soluble form of the enzyme that can be secreted (29) . Digestion with furin results in cleavage of (rh) proGDF5, and the release of mature GDF5 ( Endogenous activation of (rh) proGDF5 by primary mesenchymal cells MMP3 and other extracellular proteases are coexpressed with proBMPs at many sites, indicating that extracellular processing and activation of BMPs is possible. We wanted to test if (rh) proGDF5 could be used as recombinant therapeutic protein and if (rh) proGDF5 can be activated by target cells. We again used the micromass culture system of chicken limb buds as a model for primary mesenchymal cells that differentiate into chondrocytes. We stimulated micromass cultures with different dosages of rhGDF5 vs (rh) proGDF5 in a range between 0.37-22.2 nM at day 1 and incubated them for 3 more days without changing the media.
Alcian blue staining revealed that (rh) proGDF5 as well as rhGDF5 induce cartilage. rhGDF5
was more potent at low concentration in comparison to proGDF5, but this effect disappears at higher concentrations (Fig. 7A,B) .
Discussion
We identified a so far undescribed mutation in GDF5 that results in an arginine to glutamine substitution at position 380 (R380Q). This amino acid change is located in direct proximity to the cleavage site at which the prodomain is cleaved from the mature GDF5 molecule. The mutation causes hypoplasia of the mesophalanges in fingers 2 in all affected individuals leading to the diagnosis of BDA2. Milder hypoplasia of mesophalanges in fingers 3, 4, and 5
indicate a clinical overlap to BDA1 and BDC. BDA2 is known to be caused by specific mutations in BMPR1B, the cognate receptor for GDF5 that result in diminished transphosphorylation by the type II receptor (BMPR2) and reduced SMAD activation (23, 24) . Recently, GDF5 was identified as a second locus for BDA2. The mutation at position L441P described to be associated with BDA2 is located in the type I receptor binding pocket resulting in a severely diminished receptor binding and thus reduced activation (22) . In contrast, loss of function mutations of GDF5 result in brachydactyly type C (BDC), a hand malformation with a distinguishable pattern of digit involvement (21, 31) . The phenotypegenotype comparison of these conditions indicates that BDA2 is caused by mutations that specifically diminish GDF5 signalling. The R380Q mutation can thus be hypothesised to result in a reduced GDF5 activation and therefore decreased signalling through BMPR1B or other receptors. The variability in the family described here suggests that other factors influence the phenotype as modifiers. Such factors are likely to alter the cleavage conditions of the mutant protein and thus interfere with the bioavailability of GDF5.
We hypothesised that the skeletal malformation was due to a diminished cleavage event at the GDF5 precursor maturation site. Based on previous studies with BMPs, we assumed that proteolytic cleavage of proGDF5 is a prerequisite to liberate biologically active mature GDF5. We therefore generated a cleavage resistant proGDF5 mutant (R380A/R381A) and compared it to the R380Q mutant and wt GDF5. As demonstrated by micromass cultures, proGDF5 has the potency to induce cartilage. In contrast, the mutants R380A/R381A and R380Q only slightly induce cartilage production. Using Western blots we can show that the majority of GDF5 is secreted by the cells as proGDF5. This is in line with the observation that unprocessed proGDF5 was the predominant form in rat brain extracts (32) . The mutants R380A/R381A and R380Q are secreted but are not properly processed. Our results indicate that the R380Q mutation results in a reduced GDF5-function caused by diminished proteolytic cleavage which is shown here to be a precondition to generate biologically active GDF5.
To further investigate the processing requirements for the generation of biologically active GDF5, we produced proGDF5 recombinantly. (33) . A similar function is likely to apply to the GDF5 prodomain.
As expected from our micromass experiments using the cleavage resistant GDF5 variants, shown that MMP3 and GDF5 play a role in intervertebral disc cells (6, 37, 38) . GDF5
deposited as a proform in the ECM is likely to become activated in degenerated tissue at sites of inflammation where elevated proteolytic enzyme activity are present (37). We were able to generate a biologically active GDF5 molecule after trypsin incubation of (rh) proGDF5. This GDF5-variant was truncated at the maturation site starting at position 395 NLKA and 398 ARCS.
Previously, we demonstrated that a genetically engineered N-terminally truncated version of the mature GDF5 (GDF5-Cys) missing the first 18 amino acids, has full biological activity in the ALP assay (39). We have shown previously that under reducing conditions mature GDF5
is degraded into thirteen trypsin cleavage fragments (27) . Here we demonstrate that the mature part of proGDF5 is not degraded after trypsin digestion under non-reducing conditions implicating that the respective trypsin cleavage sites are hidden in the cystine-knot structure.
In contrast to furin and MMP3, trypsin digests proteins after basic amino acids and therefore degrades the complete prodomain of proGDF5 and the N-terminal part of mature GDF5 into small peptide fragments. Only the cystine-knot structure of the mature GDF5 domain is protected against the trypsin digestion. In comparison, furin cleavage liberates the prodomain as a larger intact protein fragment. It was shown for BMP2 that the N-terminus of the mature domain has an affinity to heparin and therefore influences its bioavailability or mobility within the ECM (40-42). On the other hand, the non-covalent association of the proteolytically liberated prodomain to the mature growth factor has been shown for other
TGFβ family members such as BMP7 (43), GDF8 (44) and TGFβ1 (45), which influences their bioavailability and/or bioactivity.
Considering the lack of conservation within the prodomains of BMPs/GDFs which is in contrast to the high conservation of the mature domains, different and specific functions of the prodomains are likely. Interestingly, proGDF5 has a heparin binding domain in the glycerol, 0.01% bromophenolblue). Micromass culture were homogenised in lysis buffer (50 mM HEPES, pH 7.5, 50 mM NaCl, 10 mM EDTA, 10% Glycerol, 1% Triton X100, complete mini (Roche), PMSF). Proteins were separated under non-reducing SDS-PAGE followed by Western blot analysis as described previously (52) . Western blotting under reducing and non-reducing conditions
Western blotting was performed as described previously (2) . The proteins were separated using 10 or 16% SDS-PAGE. Blotting onto PVDF membranes (Millipore) was carried out in the presence of 10 mM DTT, when the polyclonal antibody chicken B pool was used, because this antibody recognizes only reduced GDF5 molecules bound. The monoclonal aMP5 does only recognize refolded GDF5 under non-reducing conditions. The antibodies were detected with a chemiluminescence detection kit (Applied Biosystems, Foster City, CA, USA).
In vitro processing of (rh) proGDF5
The in vitro digestion of (rh) proGDF5 was performed with the proteases trypsin, furin and MMP-3. Proteolytic cleavage with trypsin was carried out with 3 µg proGDF5 dissolved in 1x buffers were adjusted to pH 10, pH 11 and pH 12.0) were used to dissolve rhGDF5 or (rh) pro agitated for 10 min, followed by centrifugation at 13.000 rpm. The supernatant was carefully removed and quantitatively analyzed by reverse phase HPLC and peak integration.
Alkaline phosphatase assay
The biological activity of (rh) proGDF5 digested with the proteases furin, trypsin and MMP3
was measured using different concentrations of digested (rh) proGDF5 on MCHT1/26 cells.
Mouse stromal MCHT1/26 cells were plated at 4.5 x 10 3 cells per well in 96-multiwell plates in cell culture medium (alphaMEM, Sigma, Taufkirchen, Germany; 2 mM L-glutamine, Invitrogen, Karlsruhe, Germany; 10% fetal calf serum, Invitrogen, Karlsruhe, Germany).
After 24h, cells were stimulated with 0.14 to 44 nM of digested proGDF5 incubated with the proteases trypisn, furin or MMP-3. As a control, undigested proGDF5 in the respective protease reaction buffer without protease and as second control reaction the respective protease without proGDF5 was used. After 72h cells were washed with PBS and extracted with alkaline phosphate buffer 1, containing 1% Nonident-40, 0.1 M glycine pH 9.6, 1 mM Figure 1 The R380Q mutation in GDF5 is associated with a brachydactyly A2 phenotype. Functional analysis of GDF5 mutant R380Q in micromass culture.
Legends to Figures
(A) Chicken micromass cultures were assayed after 6 days for extracellular matrix production. Cells were infected with virus containing wtGDF5 or the mutants R380Q
and R380A/R381A. Note severely diminished biological activity of the mutants.
Every condition was tested in quadruplets.
(B) Alcian blue incorporation into the extracellular matrix of micromass cultures reflecting the production of proteoglycan-rich cartilaginous matrix measured at day 6 was quantified after extraction. ProGDF5 displays biological activity whereas the R380Q and R380A/R381A mutant shows only small effects on matrix production. We performed an unpaired two-tailed t-test comparing each mutant to wtGDF5. The reduction of biological activity was highly significant (p<0.0001).
(C) Western blot analysis of GDF5 secretion under non-reducing conditions. wt GDF5
as well as the GDF5 mutants R380Q and R380A/R381A are expressed and secreted in the culture media of micromass cultures. Note that only wt GDF5 is processed and shows a band at 25 KDa.
Figure 4
Production of recombinant proGDF5.
(A) E. coli strains BL21 (DE3) and Rosetta were induced with IPTG to express (rh)
proGDF5. Bacterial pellets were separated under reducing conditions on a 16%
acrylamide SDS gel. The proteins were detected using the polyclonal antibody anti rhGDF5.
(B) Refolding of proGDF5. Inclusion bodies were dissolved in refolding buffer and direct refolding procedure was monitored for 5 days. Proteins were separated under non-reducing conditions on a 10% acrylamide SDS gel followed by Coomassie Blue staining. 
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(C) The purity of (rh) proGDF5 was monitored by SDS PAGE analysis. After the final chromatography purification process 0.3 µg rhGDF5 and 3.0 µg (rh) proGDF5 were separated under non-reducing conditions on a 10% SDS-PAGE followed by Coomassie Blue staining. Figure 5 Solubility profile of (rh) proGDF5.
The solubility profile of (rh) proGDF5 was analyzed over a pH range of 2.0 to 12.0.
For each pH value the solubility was determined in triplicate. For better comparison, the solubility profile of the mature rhGDF5 was integrated into the chart (27) . In contrast to rhGDF5, (rh) proGDF5 is soluble under physiological conditions (PBS buffer, pH 7) and insoluble at pH 10, which is the predicted pI. Functional analysis of rhGDF5 and (rh) proGDF5 in micromass cultures.
(A) Chicken micromass cultures were assayed after 4 days for extracellular matrix production. Cells were treated at day 1 with recombinant proteins and further incubated for 3 days. Every condition was performed in triplicates.
(B) Alcian blue incorporation into the extracellular matrix of micromass cultures reflecting the production of proteoglycan-rich cartilaginous matrix measured at day 4 was quantified after extraction. Note, (rh) proGDF5 showed a slightly diminished activity at low concentrations in comparison to rhGDF5, but the differences level out at higher concentrations. 
